Ginkgo Biloba 240 mg: What the Evidence Actually Supports

Evidence verdict: 240 mg/day is a recurring research dose for the standardized extract EGb 761, especially in dementia trials. It is not a universal “effective dose” of Ginkgo biloba. The strongest proof is a contradiction that only looks strange if dose is separated from clinical context: several 240 mg/day EGb 761 trials report symptom benefits in people who already have dementia, while the large 3,069-person GEM trial used the same standardized extract at the same total daily dose and found no prevention of dementia and no slowing of cognitive decline. In healthy adults, meta-analysis does not support Ginkgo as a reliable nootropic. In MCI, the 2026 Cochrane review says there is probably little or no six-month benefit. In dementia, low-certainty evidence suggests possible small-to-moderate symptomatic benefit.

Quick answer: what does “Ginkgo biloba 240 mg” actually mean?

It only becomes meaningful when four other details are attached:

1. Which product/extract? Much of the positive disease-treatment literature used EGb 761, a standardized extract.
2. Who was studied? Healthy adults, people with MCI, and people with dementia have different evidence.
3. What outcome? Symptom treatment, dementia prevention, cognitive-decline prevention, and healthy-person “focus” are different questions.
4. How long? Most positive dementia trials lasted about 22–24 weeks, while GEM followed people for a median of 6.1 years.

The milligram number by itself does not answer any of those questions.

---

The 2026 Cochrane review should control the overall interpretation

The current top-level synthesis is the 2026 Cochrane review of 82 studies and 10,613 participants. Seventy-two studies with 9,783 participants contributed extractable data, but only four studies were judged low risk of bias across all assessed domains. PubMed 41641880

Its conclusions are deliberately population-specific:

• Mild cognitive impairment: moderate-certainty evidence suggests Ginkgo probably has little or no effect at six months on global clinical status, cognition, or activities of daily living.
• Dementia: low-certainty evidence suggests possible small-to-moderate six-month benefits in global status, cognition, and activities of daily living.
• Cognitive complaints without a clear diagnosis: evidence remains uncertain.
• Adverse events: overall trial evidence does not show a large common adverse-event excess, but this does not eliminate medication-specific or rare risks.

That hierarchy should outrank isolated positive trials when the question is “Does Ginkgo work?”

---

Why 240 mg shows up so often

The positive side: dementia symptom trials

A 24-week multicenter double-blind placebo-controlled trial randomized 410 outpatients with mild-to-moderate dementia and neuropsychiatric symptoms to 240 mg/day EGb 761 or placebo. The EGb 761 group improved more on the SKT cognitive test and Neuropsychiatric Inventory, with favorable secondary functional and quality-of-life measures. PubMed 22459264

Another 24-week randomized trial of 404 outpatients used 240 mg/day and reported favorable cognition and neuropsychiatric outcomes in both Alzheimer and vascular-dementia subgroups. PubMed 22086747

An earlier 400-person double-blind trial in dementia with neuropsychiatric features also reported favorable outcomes with EGb 761. PubMed 17341003

A meta-analysis of four placebo-controlled trials involving 1,628 dementia patients found favorable pooled neuropsychiatric-symptom results; all included trials used 240 mg/day. PubMed 28931444

The newer mild-dementia meta-analysis pooled four eligible trials / 782 patients and likewise reported favorable cognition, global assessment, activities of daily living, and quality-of-life outcomes with 240 mg/day EGb 761. PubMed 39895346

The critical context: this is standardized-extract disease-treatment evidence

These findings are not evidence that:

• every 240 mg Ginkgo capsule is equivalent;
• healthy adults should expect better memory;
• 240 mg prevents dementia;
• 240 mg is an optimal dose across extracts; or
• a person with cognitive symptoms should self-treat instead of getting evaluated.

The intervention is better described as 240 mg/day of a particular standardized extract in selected dementia populations for about six months.

---

The most important contradiction: GEM also used EGb 761 at 240 mg/day—and was negative

The Ginkgo Evaluation of Memory (GEM) study enrolled 3,069 adults age 75 or older with normal cognition or MCI and followed them for a median of 6.1 years. Participants received 120 mg EGb 761 twice daily—240 mg/day total—or placebo. PubMed 19017911

It did not reduce:

• all-cause dementia incidence;
• Alzheimer disease incidence; or
• progression from baseline MCI to dementia.

For all-cause dementia, the hazard ratio was 1.12 (95% CI 0.94–1.33). PubMed 19017911

A subsequent GEM analysis found no slowing of decline in:

• memory;
• attention;
• language;
• executive function; or
• global cognition. PubMed 20040554

Why this is such an important evidence lesson

The nominal dose and standardized extract were highly relevant, but the clinical question changed:

• dementia trials asked whether symptoms could improve over months in people who already had disease;
• GEM asked whether years of exposure could prevent dementia or cognitive decline in older adults without dementia.

A positive treatment result and a negative prevention result are not contradictory once the outcome is defined properly.

This is also why search snippets saying “240 mg is the effective Ginkgo dose” are scientifically incomplete.

---

Healthy adults: 240 mg does not rescue the nootropic claim

A 2012 meta-analysis of randomized trials in healthy participants found effect estimates that were non-significant and close to zero for memory, executive function, and attention. The analyses included 1,132 participants for memory, 534 for executive function, and 910 for attention. PubMed 23001963

Importantly, the meta-analysis found no relationship between cognitive effect size and daily dose, total dose, age, trial duration, or sample size.

An earlier systematic review similarly concluded that isolated acute positive findings at particular doses/time points were not consistently replicated and that longer-term healthy-person evidence was largely negative. PubMed 17480002

So “take the dementia-trial dose for focus” is not an evidence-based inference.

---

Mild cognitive impairment: one positive 240 mg trial does not outweigh the total evidence

A 24-week double-blind multicenter trial randomized 160 people with MCI plus neuropsychiatric symptoms to 240 mg/day EGb 761 or placebo. It reported favorable changes on the Neuropsychiatric Inventory and selected cognitive/global measures. PubMed 24633934

That is valid product-specific evidence.

But the 2026 Cochrane review included 12 MCI studies / 1,913 participants and concluded that Ginkgo probably has little or no six-month effect on global clinical status, cognition, or activities of daily living. PubMed 41641880

The appropriate hierarchy is therefore:

individual positive MCI signal < broader moderate-certainty MCI synthesis

That is not “ignoring” the favorable trial. It is weighting the full literature appropriately.

---

Dementia after stroke: a newer positive subgroup analysis still needs dedicated trials

A 2026 pooled meta-analysis focused on 488 dementia patients with previous cerebral infarction confirmed by neuroimaging. It reported statistically significant benefits of 240 mg/day EGb 761 for cognition, activities of daily living, and global clinical impression, with adverse-event rates similar to placebo. PubMed 41908799

The authors also said dedicated clinical trials are needed to confirm the finding.

That qualification matters because pooled subgroup analyses can identify a potentially responsive population without proving that the subgroup effect will replicate prospectively.

---

EGb 761 is not a synonym for “Ginkgo biloba”

EGb 761 is a standardized Ginkgo leaf extract used repeatedly in clinical research. In GEM, the study product was independently procured to meet prespecified composition standards and was standardized to major flavone glycosides and terpene lactones.

A generic 240 mg leaf powder, tincture, or differently manufactured extract may not match:

• extraction process;
• constituent profile;
• ginkgolic-acid limits;
• batch consistency;
• bioavailability; or
• the studied tablet formulation.

That means an online listing or Supplement Facts panel saying “Ginkgo biloba — 240 mg” does not establish equivalence to EGb 761.

Evidence concentration also matters

The recent mild-dementia meta-analysis is explicitly focused on EGb 761, and one author is affiliated with Dr. Willmar Schwabe, the company associated with that standardized extract. PubMed 39895346

A company-affiliated evidence base is not automatically invalid. It does make independent replication, product specificity, and conflict disclosure especially important when turning a branded-extract literature into a general supplement claim.

---

Safety: the bleeding story is more nuanced than “Ginkgo thins the blood”

NCCIH states that Ginkgo leaf extract is generally well tolerated in moderate amounts, with dizziness, gastrointestinal symptoms, and headache among the more common side effects. Research exposures have extended as long as six years. NCCIH

NCCIH also warns that Ginkgo may increase bleeding risk in people taking anticoagulants such as warfarin and can interact with other medications. NCCIH

Randomized hemostasis data do not show a simple universal bleeding effect

A meta-analysis of 18 randomized controlled trials / 1,985 adults examined platelet aggregation, fibrinogen, PT, aPTT, and related hemostasis measures. It did not find evidence that standardized Ginkgo extract produced a clinically meaningful increase in bleeding-related hemostasis risk overall. PubMed 21923430

A small randomized crossover study in 12 healthy men also found that Ginkgo pretreatment did not materially alter INR, platelet aggregation, or warfarin pharmacokinetics after a single warfarin dose. PMC

Why the medication warning still stands

Those studies do not prove that Ginkgo is universally safe with chronic warfarin therapy in older adults with comorbidities. Small healthy-volunteer pharmacology studies and aggregate hemostasis markers answer different questions from real-world major bleeding.

The correct conclusion is not “Ginkgo definitely causes bleeding” or “Ginkgo definitely does not interact with warfarin.” It is:

• randomized hemostasis data are more reassuring than folklore suggests;
• authoritative interaction guidance still advises caution with anticoagulants; and
• a medication-specific decision belongs with the prescriber/pharmacist rather than a universal supplement rule.

This page therefore does not give a fixed “stop X days before surgery” instruction.

---

Ginkgo seeds are a different exposure from standardized leaf extract

NCCIH notes that fresh Ginkgo seeds are toxic when consumed orally, and serious reactions have also occurred with roasted seeds or crude plant material. NCCIH

That should not be confused with the standardized leaf extracts used in the cognition/dementia trials.

This distinction cuts both ways:

• seed toxicity should not be used to imply that EGb 761 has the same exposure profile;
• leaf-extract trial safety should not be used to claim that Ginkgo seeds are safe.

Pregnancy is another separate evidence boundary: NCCIH says Ginkgo may be unsafe in pregnancy because of potential early labor or extra bleeding around delivery, and breastfeeding evidence is sparse.

---

“Better circulation” is not a substitute for cognitive outcomes

Ginkgo has been studied in vascular pathways and in intermittent claudication/peripheral arterial disease. Older randomized-trial meta-analysis found changes in pain-free walking distance. PubMed 11014719

That disease-specific walking outcome does not establish that healthy users get:

• better cerebral perfusion;
• better memory;
• more focus;
• dementia prevention; or
• a noticeable “brain blood-flow” effect.

Mechanisms can explain why a trial is plausible. They cannot replace the trial’s actual endpoint.

---

Evidence applicability ledger

---

Frequently asked questions

Is Ginkgo biloba 240 mg effective?

For what? In dementia symptom trials using standardized EGb 761, 240 mg/day has produced favorable outcomes in several studies. The same 240 mg/day EGb 761 failed to prevent dementia or cognitive decline in the large GEM study. Dose without outcome is an incomplete question.

Is 240 mg better than 120 mg?

The literature does not establish a universal dose-response rule across products and uses. Many dementia studies used 240 mg/day, but that does not prove that doubling a different retail product produces greater benefit.

Does 240 mg Ginkgo improve memory in healthy adults?

No convincing evidence supports that claim. Meta-analysis in healthy people found non-significant effects close to zero for memory, executive function, and attention. PubMed 23001963

Does Ginkgo prevent dementia?

No. GEM randomized 3,069 older adults to 240 mg/day EGb 761 or placebo for a median of 6.1 years and found no reduction in dementia or Alzheimer disease incidence. PubMed 19017911

What about mild cognitive impairment?

The 2026 Cochrane review concludes that Ginkgo probably has little or no effect at six months on global status, cognition, or activities of daily living in MCI, despite positive findings from some individual studies. PubMed 41641880

Is EGb 761 the same as generic Ginkgo?

No. EGb 761 is a standardized extract with a defined manufacturing/constituent profile. Generic powders and other extracts should not automatically inherit its trial results.

Does Ginkgo increase bleeding?

The answer is nuanced. A randomized-trial meta-analysis did not show clinically meaningful changes in major hemostasis markers overall, but NCCIH still cautions about bleeding risk with anticoagulants such as warfarin. Medication-specific review is appropriate. PubMed 21923430 · NCCIH

---

Bottom line

“Ginkgo biloba 240 mg” is a dose label, not an evidence conclusion.

The strongest interpretation in 2026 is:

• 240 mg/day EGb 761 is the best-studied exposure in several dementia symptom trials;
• those trials provide a real but low-certainty symptomatic signal;
• the same 240 mg/day standardized extract failed to prevent dementia or cognitive decline in GEM;
• healthy-person cognitive enhancement is not supported convincingly;
• MCI overall probably does not improve meaningfully at six months;
• generic 240 mg retail products should not inherit EGb 761 evidence automatically; and
• safety is generally reassuring in trials, but anticoagulant use, pregnancy, product identity, and seed exposure require separate caution.

That context is what the number 240 mg actually needs.

---

References

1. Wieland LS, et al. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2026. PMID 41641880
2. Riepe M, et al. EGb 761 in mild dementia: pooled randomized-trial meta-analysis. 2025. PMID 39895346
3. DeKosky ST, et al. Ginkgo biloba for prevention of dementia: the GEM trial. JAMA. 2008. PMID 19017911
4. Snitz BE, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA. 2009. PMID 20040554
5. Laws KR, et al. Is Ginkgo biloba a cognitive enhancer in healthy individuals? 2012. PMID 23001963
6. Canter PH, Ernst E. Ginkgo biloba is not a smart drug. 2007. PMID 17480002
7. Gavrilova SI, et al. EGb 761 in MCI with neuropsychiatric symptoms. 2014. PMID 24633934
8. Herrschaft H, et al. EGb 761 240 mg/day in dementia with neuropsychiatric features. 2012. PMID 22459264
9. Ihl R, et al. Once-daily EGb 761 in Alzheimer and vascular dementia. 2012. PMID 22086747
10. Gauthier S, Schlaefke S. EGb 761 and behavioral/neuropsychiatric symptoms of dementia: meta-analysis. 2018. PMID 28931444
11. EGb 761 in dementia with previous cerebral infarction: pooled meta-analysis. 2026. PMID 41908799
12. NCCIH. Ginkgo: Usefulness and Safety. Updated 2025. Source: nccih.nih.gov
13. Kellermann AJ, Kloft C. Bleeding risk with standardized Ginkgo extract: systematic review and meta-analysis. 2011. PMID 21923430
14. Effect of ginkgo and ginger on warfarin pharmacokinetics/pharmacodynamics in healthy subjects. PMC1884814
15. Napryeyenko O, Borzenko I. Ginkgo special extract in dementia with neuropsychiatric features. 2007. PMID 17341003
16. Pittler MH, Ernst E. Ginkgo for intermittent claudication: meta-analysis. 2000. PMID 11014719

Related Articles

• Best Nootropics for Focus
• Lion's Mane: Evidence Guide
• Creatine for Brain Health
• NMN and NAD+: Evidence Review